SPP1 and neoplasm: 4-1BB–OPN was tested in vivo in mice with established GL261 GBM cells: the authors solidly demonstrated that the treatment drastically increases survival time by 68%, so is a promising approach to potentiate naturally occurring antitumor immunity via tumor targeting [43].